Loading...
Images of Adam Feuerstein
(1 - 6 from 6 )
News
New FDA lung cancer OK for Celgene's Abraxane should boost sales
www.fiercepharma.com
[FiercePharma] - A much bigger payout, though, could depend on a late-stage study of pancreatic cancer. Success in this indication is seen by some analysts, including TheStreet's Adam Feuerstein, as a potential winner for investors hanging on to the Celgene CVR.
Google News: Amarin (AMRN) Ticks Lower as NCE Status Called into Question by Noted ...
[StreetInsider.com (subscription)] - Amarin Corp Plc (NASDAQ: AMRN) shares are volatile as biotech investor Adam Feuerstein is holding a live Q&A session today. Currently, the topic is Amarin. Feuerstein now thinks NCE is not going to happen for the pharma. He thinks the extended delay in
sorted by relevance / date